Virupaksha Organics IPO

The IPO for Virupaksha Organics is an entirely book-built offering of shares, with up to ₹400 crore coming from a fresh equity offering and an additional 10,740,000 shares being offered through an OFS. The company's draft red herring prospectus was submitted to SEBI on September 29, 2025. Proceeds from the newly issued shares will support the company; proceeds from the OFS will benefit the selling shareholders.

The Virupaksha Organics IPO is classified as a book-building IPO, although pricing of the securities, timing of the offer, and anticipated listing date were not provided in the manner provided for in the DRHP. It is anticipated that the equity securities will be traded on the NSE platform. GYR Capital Advisors Pvt Ltd. acts as the book-running lead manager for the offering, while Bigshare Services Pvt Ltd. will serve as the registrar to the offer.

Company Background

Incorporated in 1997 in Hyderabad. India’s pharma world, Virupaksha Organics, began as a modest chemical manufacturer. Over the last 28 years, they have undergone a profound transformation. They have evolved tremendously within 28 years and no longer represent just the production element but have also become a research-oriented organization composed of professionals from various fields dedicated to the application of pharmaceutical science. The unique feature of this organisartion is that it has remained focused on one primary objective throughout its evolution, developing quality active pharmaceutical ingredients (APIs) and their intermediates, which support the operation of the healthcare sector. From their roots in Hyderabad, they expand all over India, alongside building deep & strong relationships with the global pharma giants who trust Virupaksha Organic for the essential building blocks of their medicine.

At the end, a belief that behind every chemical compound is a commitment to bettering human health through precision and passion.

Operations & Product Range

The operations involve the manufacturing of APIs across various therapeutic segments, which include anti-histamine, anti-fungal and anti-diabetic treatments, among others. By focusing on these specific therapeutic areas, the company serves organic facilities to the global health needs, providing the raw pharmaceutical materials that eventually reach patients as finished dosage forms.

The company serves a diverse set of customers, ranging from the large domestic pharmaceutical firms to the international healthcare companies. Their business model relies on technical expertise in organic chemistry and the ability to manufacture complex molecules at scale, which is a key driver behind the Virupaksha Organics IPO.

Facilities & Capacity

Virupaksha Organics Ltd. operates 4 manufacturing facilities located in Telangana and Andhra Pradesh. These are designated as Unit I (IDA Gandhinagar), Unit II (Pashamylaram), Unit III (Kazipally) and Unit IV (Atchutapuram). These facilities are engaged with versatile reactor systems that must be capable of handling a wide range of chemical reactions.

At the end of 2025, the company had a total installed reactor capacity of 1,185.35 KL. A major focus of the upcoming IPO of their company is the establishment of a new manufacturing unit at Atchutapuram in Andhra Pradesh, which is intended to significantly boost the company's output and help meet the rising global demand for its products.

Brands & Market Presence

The market presence of Virupaksha Organics Ltd. is remarkable. The company maintains several quality certifications required to operate in highly regulated markets, as they need to show the client that they not only come with goodwill, but they also have the capability, which is shown in their certification and stamps.

In the 2025 financial year, exports accounted for 51.52% of the total revenue from operations, reflecting a strong international footprint. This domestic and export balance allows it to hedge against regional market fluctuations and tap into the growing pharmaceutical sectors of North America, Europe and Asia.

Revenue Streams & Business Model

Virupaksha Organics' revenue generation is from the sale of APIs and pharmaceutical intermediaries; their earnings are geographically diversified, with a near-even split between Indian sales and international exports. This model provides stability and access to high-margin opportunities in regulated foreign markets.

For the 2025 fiscal year, this company has generated revenue from operations of ₹5,471.93 million, compared to ₹4,890.15 million in 2024 and ₹4,215.60 million in 2023. Profitability has followed a similar path, with the profit after tax (PAT) growing from ₹450.25 million in 2023 to ₹655.48 million in 2025.

Management & Shareholding

Promoters & Shareholding

The promoters of the company include Chandra Mouliswar Reddy Gangavaram, Balasubba Reddy Mamilla and several other members of the Gangavaram and Mamilla families. In the company, they collectively bring an extensive experience in chemical engineering and pharmaceutical management. Before the IPO of the company, the promoters held a heavy stake in the equity of the company, but after the IPO, the promoters' holding will reduced to the new public.

Board & Key Management

The board & key management of the company are led by Chandra Mouliswar Reddy Gangavaram (Managing Director). The leadership team is made up of the executive directors with technical backgrounds and independent directors who provide oversight in areas such as audit, risk management and corporate governance.